Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 02 - 01 save search
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
Published: 2021-02-01 (Crawled : 22:01) - globenewswire.com
PRTA 4 | $20.56 -3.43% -3.53% 440K
|
Health Technology
|
| O: 31.0%
H: 3.96%
C: -0.42%
fda phase 3 als
Neogen relaunches FDA-approved ThyroKare™ tablets for dogs
Published: 2021-02-01 (Crawled : 16:00) - biospace.com/
NEOG P | $12.31 4.5% 4.23% 2.7M
|
Health Technology
|
| O: 0.75%
H: 3.23%
C: 0.6%
fda approval fda approval
SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors
Published: 2021-02-01 (Crawled : 15:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: 0.54%
H: 4.99%
C: 1.45%
fda clearance fda biotech trial application clearance
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update AMZEEQ®
Published: 2021-02-01 (Crawled : 14:00) - biospace.com/
VYNE | $2.345 -0.21% -0.21% 30K
|
Health Technology
|
| O: 6.06%
H: 11.9%
C: 9.52%
fda approval fda approval
Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
Published: 2021-02-01 (Crawled : 13:03) - globenewswire.com
ZSAN | $0.5576 7.23% -5.85%
|
Health Technology
|
| O: 21.77%
H: 0.0%
C: -12.5%
fda submission resubmission pharma
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN
Published: 2021-02-01 (Crawled : 13:03) - globenewswire.com
ADMA 4 | $6.54 5.48% 5.13% 2.5M
|
Health Technology
|
| O: 5.86%
H: 5.53%
C: 4.26%
fda approval fda approval
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
Published: 2021-02-01 (Crawled : 13:03) - globenewswire.com
VYNE | $2.345 -0.21% -0.21% 30K
|
Health Technology
|
| O: 6.06%
H: 11.9%
C: 9.52%
fda approval fda approval therapeutics
Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA
Published: 2021-02-01 (Crawled : 12:03) - globenewswire.com
KMDA | $5.1 0.99% -0.99% 5.3K
|
Health Technology
|
| O: 8.35%
H: 1.0%
C: -2.85%
fda blood license research
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.